GLYC — GlycoMimetics Income Statement
0.000.00%
Last trade - 00:00
- $105.70m
- $63.91m
- $0.01m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 10.2 | 1.16 | 0.075 | 0.01 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 61.4 | 61.7 | 64.6 | 47.5 | 39.3 |
Operating Profit | -61.4 | -51.5 | -63.4 | -47.4 | -39.3 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -57.9 | -51 | -63.4 | -46.7 | -36.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -57.9 | -51 | -63.4 | -46.7 | -36.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -57.9 | -51 | -63.4 | -46.7 | -36.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -57.9 | -51 | -63.4 | -46.7 | -36.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.34 | -1.12 | -1.23 | -0.889 | -0.583 |